Atara biotherapeutics presents positive tab-cel® long-term overall survival data for epstein-barr virus-driven post-transplant lymphoproliferative disease after solid organ transplant at atc 2021 virtual connect

South san francisco, calif.--(business wire)--atara biotherapeutics, inc. (nasdaq: atra), a pioneer in t-cell immunotherapy, leveraging its novel allogeneic ebv t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced a combined long-term overall survival (os) analysis from three clinical studies of tabelecleucel (tab-cel®) in patients with epstein-barr virus-driven post-transplant lymphoproliferative disease (ebv+ ptld) after solid o
ATRA Ratings Summary
ATRA Quant Ranking